ICGT ICG Enterprise Trust

ICG Enterprise Trust Plc: Portfolio Update

ICG Enterprise Trust Plc: Portfolio Update

ICG Enterprise Trust plc

8 February 2021

Portfolio Update

Realisation of Telos generates estimated 29.5p per share uplift in NAV

ICG Enterprise Trust (“ICGT”) is pleased to announce that it has realised its holding in Telos Corporation (“Telos”), generating net cash proceeds to ICGT of c. £40m.

ICGT estimates that the uplift from this realisation relative to ICGT’s net asset value at 31 October 2020 is c. 2.4%, or 29.5p per share.

At ICGT’s Q3 results for the period ended 31 October 2020 (announced on 4 February 2021), Telos was ICGT’s 4th largest underlying investment and represented c. 2.9% of ICGT’s Portfolio Value.  The investment was realised at a c. 33x multiple of initial cost.

Oliver Gardey, Head of Private Equity Fund Investments at ICG, commented:

“Since the IPO of Telos in November 2020 we have been actively considering options to maximise the risk-adjusted return to our shareholders.

“This transaction crystallises a significant value uplift and provides ICG Enterprise Trust with substantial additional liquidity to take advantage of our growing pipeline of investment opportunities.”

Enquiries

Analyst / Investor enquiries:                                                                                              +44 (0) 20 3545 2000

Oliver Gardey, Head of Private Equity Fund Investments, ICG    

Colm Walsh, Managing Director, ICG                                         

James Caddy, Investor Relations, ICG                                                               

Media:

Fiona Laffan, Global Head of Corporate Affairs, ICG                                                        +44 (0) 20 3545 1510

Ed Gascoigne Pees, Eddie Livingstone-Learmonth, Camarco                                          +44 (0) 20 3757 4993

Disclaimer

This report may contain forward looking statements. These statements have been made by the Directors in good faith based on the information available to them up to the time of their approval of this report and should be treated with caution due to the inherent uncertainties, including both economic and business risk factors, underlying such forward-looking information. These written materials are not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption therefrom. The issuer has not and does not intend to register any securities under the US Securities Act of 1933, as amended, and does not intend to offer any securities to the public in the United States. No money, securities or other consideration from any person inside the United States is being solicited and, if sent in response to the information contained in these written materials, will not be accepted.

 



EN
08/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ICG Enterprise Trust

 PRESS RELEASE

Director/PDMR Shareholding

Director/PDMR Shareholding ICG Enterprise Trust plc (the “Company”) 2 April 2026 Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them The Company received notification on 1 April 2026 that Jane Tufnell, Chair, transferred 13,283 ordinary shares in the Company ("Shares") from a General Investment Account (“GIA”) to an Individual Savings Account (“ISA”), and that she transferred 6,380 Shares to a person closely associated (“PCA”) with her, who subsequently transferred those 6,380 Shares from a GIA to ...

Mark Thomas ... (+3)
  • Mark Thomas
  • Martin Hall
  • Mike Foster

Hardman & Co Monthly: April 2026

Feature article: 2025 pharma statistics, by Dr Martin Hall, Head of Life Sciences at Hardman & Co Our pharmaceutical dataset has been compiled over 40 years from 109 companies, which, through M&A activity and consolidation, now comprise 46 companies. An efficient reporting system has seen all the listed multinational pharma companies announce results for 2025, giving us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of global pharmac...

 PRESS RELEASE

Voting Rights and Capital

Voting Rights and Capital ICG Enterprise Trust plc (the “Company”) 1 April 2026 Total Voting Rights In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R, the Company announces as follows. At the close of business on 31 March 2026, the Company had 63,554,192 Ordinary shares in issue, of which 2,074,106 were held in Treasury. Therefore, the total number of voting rights in the Company is 61,480,086.The above figure 61,480,086 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their intere...

 PRESS RELEASE

Transaction in Own Shares

Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 31 March 2026 Transaction in Own Shares The Company announces that on 30 March 2026 it bought back 15,000 of its own shares, to be held as treasury shares, at an average price of 1330 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 2,089,106Total shares in issue excluding treasury shares following settlement of this purchase: 61,465,086 The Company has bought back these shares under the authority granted by shareholders at i...

 PRESS RELEASE

Transaction in Own Shares

Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 25 March 2026 Transaction in Own Shares The Company announces that on 24 March 2026 it bought back 15,000 of its own shares, to be held as treasury shares, at an average price of 1327 pence per share. Further details are set out below: Number of shares held as treasury shares following settlement of this purchase: 2,074,106Total shares in issue excluding treasury shares following settlement of this purchase: 61,480,086 The Company has bought back these shares under the authority granted by shareholders at its Annual Ge...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch